On the basis of the results from the QuANTUM-R study and a phase 2 study in Japan in patients with relapsed/refractory FLT3-ITD–positive AML, quizartinib was approved in Japan in June 2019 [11]. The gene discussed is FLT3; the disease is acute myeloid leukemia.